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Abstract Idiopathic nephrotic syndrome (INS) is one of the
most common renal diseases found in the paediatric popula-
tion and is associated with significant complications, includ-
ing infection and thrombosis. A high proportion of children
enter sustained remission before adulthood, and therapy must
therefore mitigate the childhood complications, while
minimising the long-term risk to health. Here we address the
main complications of INS and summarise the available evi-
dence and guidance to aid the clinician in determining the
appropriate treatment for children with INS under their care.
Additionally, we highlight areas where no consensus regard-
ing appropriate management has been reached. In this review,
we detail the reasons why routine prophylactic antimicrobial
and antithrombotic therapy are not warranted in INS and em-
phasise the conservative management of oedema. When phar-
macological intervention is required for the treatment of oe-
dema, we provide guidance to aid the clinician in determining
the appropriate therapy. Additionally, we discuss obesity and
growth, fracture risk, dyslipidaemia and thyroid dysfunction
associated with INS. Where appropriate, we describe how
recent developments in research have identified potential nov-
el therapeutic targets.
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Introduction
Nephrotic syndrome (NS) is one of the most common causes
of chronic kidney disease (CKD) in the paediatric population.
The cardinal features are oedema, massive proteinuria and
hypoalbuminaemia. Children with NS have a decreased qual-
ity of life [1], are at risk of a wide range of complications
associated with significant morbidity and experiencemortality
rates of up to 2.7 % [2].
NS can be divided into congenital NS (presentation before
3months of age), infantile NS (presentation between 3months
to 1 year of age) and idiopathic NS (INS). The largest of these
groups is INS, and initial management involves an 8- to 12-
week course of oral glucocorticoid (Gc) therapy [3–5]. Ap-
proximately 92 % of children with INS will enter remission
during this initial treatment and are subsequently classified as
having steroid-sensitive nephrotic syndrome (SSNS), while
8 % fail to enter remission and are classified as having
steroid-resistant nephrotic syndrome (SRNS) [6].
Steroid-sensitive nephrotic syndrome
Data from the 1960s reveal that the most common histological
diagnosis in SSNS is minimal change disease (MCD), where
glomeruli appear normal under light microscopy, but
podocyte foot process effacement is detectable by electron
microscopy [7]. In current clinical practice, children who enter
disease remission during the initial course of Gc therapy do
not require a kidney biopsy (unless there are atypical features),
as initial clinical response to Gc therapy in children is of
greater prognostic significance than histological findings
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[8, 9]. Children with SSNS generally have a favourable out-
come, and the results of older studies suggested they achieve
long-term remission during teenage years [10]. However, re-
cent data suggest that over 30 % of SSNS children relapse in
adulthood [11, 12].
Steroid-resistant nephrotic syndrome
The most common histological diagnosis in SRNS is focal
segmental glomerulosclerosis, a term which in practice
(though not strictly correctly) is used interchangeably with
SRNS [7, 13]. Children with SRNS are treated with a range
of other (non-Gc) immunomodulatory agents, including my-
cophenolate mofetil, cyclophosphamide, ciclosporin and ri-
tuximab [14]. More than 60 % of children with SRNS who
fail to achieve remission with pharmacological intervention
will progress to end-stage renal disease [15]. There are also
differences in mortality rates according to initial response to
Gc therapy: 2.7 % in the INS population overall, 18.5 % in
children with SRNS, 6.3 % in children with early relapse
following initial remission and 0.4 % in children without early
relapse [2].
Over the past 15 years genetic discoveries have vastly im-
proved our understanding of the molecular basis of NS. The
PodoNet consortium has recently reported data from a hetero-
geneous population of 1655 children with SRNS with a me-
dian follow-up time of 3.7 years. In this series, SRNS was
either congenital (6 %), infantile (7 %), adolescent onset
(13 %) or childhood onset (74 %). At the time of last fol-
low-up, 11.7 % of the children required dialysis, 14.2 % had
received a kidney transplant and 2.3 %were deceased [16]. Of
note, 23.6 % of children from this heterogeneous SRNS co-
hort had a genetic mutation, in contrast to another series where
mutations were found in 66 % of NS cases presenting under
the age of 1 year [17]. The most common mutations in child-
hood NS are found in genes encoding nephrin (NPHS1),
podocin (NPHS2) and Wilms tumour 1 (WT1) [13]. The in-
creasing availability of genetic testing in SRNS will help cli-
nicians minimise exposure to immunosuppressive agents
since genetic mutations are associated with a poor response
to immunosuppression [18].
INS guidelines
Children with INS are at risk of significant complications,
including infection, thromboembolism and dyslipidaemia,
and while there are a number of international guidelines for
the management of INS [9, 14, 19, 20], few provide guidance
regarding the non-immunosuppressive therapy applicable for
INS. Here, we review the available literature on non-
immunosuppressive treatment options for INS and highlight
areas requiring further research.
Infection
The leading cause of mortality in the childhood INS popula-
tion is infection, and the annual incidence of invasive bacterial
infection is approximately 1–2 % [2, 21]. Accordingly, the
parents of any child with INS should be advised to seek med-
ical review if their child develops a fever [9]. The International
Study of Kidney Disease in Children (ISKDC) followed al-
most 389 children with MCD for 5–10 years and reported ten
deaths, of which six were due to infection [2]. The importance
of infection in INS is further underscored by the observation
that the first significant reductions in mortality occurred with
the introduction of antimicrobial agents in the 1940s before
the widespread use of Gc therapy [22]. Viral infection also
poses a significant hazard to children with INS. Varicella zos-
ter virus (VZV), measles or influenza can have devastating
consequences in immunosuppressed children with INS, in-
cluding severe pulmonary disease, multi-organ failure and
even death [23, 24]. Potential reasons for the increased rates
of infection in NS include disturbances of the complement
system [25], defective opsonisation and altered T-cell function
[26]. However, strongly persuasive data implicating these pos-
sible causes are lacking. Several studies have shown an asso-
ciation between infection and altered serum concentrations of
immune-related proteins in children with INS, but none have
proven a definitive causal link [25, 27]. For example,
hypogammaglobulinaemia is a prominent feature of INS in
both relapse and remission. Kemper et al. studied serum im-
munoglobulins, including immunoglobulin G (IgG) sub-
classes, in 44 children with SSNS and found that early phases
of relapse were characterised by reduced IgG-1, while later
phases were characterised by deficiency of IgG-1–3 [28]. De-
ficiency of IgG-2 persisted for up to 1 year into remission.
This altered IgG subclass constitution may result in increased
susceptibility to infection. Children with INS are at a higher
risk of infection during periods of oedema, but whether the
oedema contributes to this increased risk or is simply a marker
of severe or unresponsive disease is unclear [21]. A further
association has been identified between children with severe
hypoalbuminaemia at initial presentation of INS and increased
risk of subsequently developing peritonitis [29].
Sites of infection
Several studies have found common sites of infection in chil-
dren with INS, however discrepancies in the results do exist.
Recent reports are from Southeast Asia, and it is therefore
unclear how transferrable these data are to the European or
U.S. setting. Furthermore, many studies are uncontrolled in
design, creating difficulties for differentiating infections com-
mon in the general paediatric population from those specific to
the INS population.
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A retrospective study from 1968 provided data from 39
episodes of infection in children with INS. Cellulitis and other
soft tissue infections were the most common (54 %), followed
by peritonitis (21 %) and nonlocalised bacteraemia (21 %)
[30]. It is unclear from these data whether the presence of
oedema was strongly associated with soft tissue infection. A
more recent study from Taiwan reviewed 28 cases of bacterial
infection in children with INS presenting over a 10-year peri-
od. The authors reported peritonitis in 13 cases, sepsis in six
cases, cellulitis in four cases, urinary tract infection (UTI) in
four cases and a single case of osteomyelitis [31]. Another
Taiwanese study reported pneumonia (49 %) to be the most
common infection in children with INS, followed by UTI,
sepsis, peritonitis and cellulitis. The authors of this latter study
also identified an association between age and site of infec-
tion: pneumonia was the most common infection in children
with INS aged <10 years, but UTI was more common in
children aged >10 years [32]. The importance of respiratory
infections in children with INS was also highlighted in a 2003
study from Pakistan which examined 74 episodes of infection
and found that acute respiratory infections (29 %) and skin
infection (27 %) were the most common, followed by diar-
rhoea (14%), UTI (13 %) and peritonitis (11 %). Two children
also had pulmonary tuberculosis [33]. An additional study
from India involving 154 children found that pulmonary tu-
berculosis was the second most common site of infection
(10 %), preceded by UTI (14 %) [34].
Regarding studies conducted in Western countries, a 1995
study from France reported 32 children with INS requiring
admission for intravenous antibiotic therapy. Half of the infec-
tions were episodes of peritonitis, with Streptococcus
pneumoniae accounting for 50 % of the causative agents
[35]. Additionally, a 2015 study from Italy reported 218 chil-
dren with a first presentation of INS. Of these 218 children, 27
(12.4 %) developed infections, with 16 children (7.3 %) hav-
ing bacterial infections (8 pneumonia, 1 peritonitis, 1 cellulitis
and 1 otitis; 5 were not specified), ten having viral infections
(enteric or upper respiratory infections and 1 case of primary
varicella infection) and one having fungal infection. No data
were provided about the causative organism [36]. Further ro-
bust data for the Western European population will become
available when the ongoing PREDNOS and PREDNOS 2
trials report their findings [37].
Causative agents
An awareness of common pathogens responsible for infec-
tions in children with INS is vital to guide initial antimicrobial
therapy. In a U.S. retrospective review focussing on primary
peritonitis in INS, S. pneumoniae was the major pathogen
identified, accounting for 38 % of cases, with Gram-negative
organisms cultured from only 3 % of children. An additional
27 % of children had negative culture results but were
clinically responsive to penicillin [38]. Another study of peri-
tonitis in children with INS found that S. pneumoniae was the
most common pathogen identified (50 %), but that
Escherichia coli accounted for 25 % of cases, and 16 % of
cases were culture-negative [39]. A recent prospective study
from Turkey monitored 268 children with newly diagnosed
INS over a 5-year period and found an incidence of peritonitis
of 2.6 %. A microorganism was identified in three out of eight
episodes of peritonitis in seven children (Streptococcus
hemolyticus , S. pneumoniae and alpha-hemolytic
Streptococcus) [40]. E. coli was identified as the most com-
mon causative agent (61 %) of UTI in children with INS, with
non-E. coli Gram-negative organisms accounting for 31 % of
culture isolates and Gram-positive organisms for 8 % [41]. A
study from Taiwan investigating ten episodes of sepsis and
eight episodes of peritonitis in 18 children with INS reported
that Gram-positive organisms (n=7, with S. pneumoniae be-
ing the most common) and Gram-negative organisms (n=7)
were found in equal numbers. Two of the four cases of
S. pneumoniae infection in this study were penicillin-
resistant [42]. Finally, a case report also documents two in-
fants with NS receiving penicillin chemoprophylaxis who de-
veloped penicillin-resistant pneumococcal peritonitis [43].
Overall, there is a preponderance of reports on S. pneumonia,
providing some justification for the use of penicillin V during
relapse of INS.
Viral infection
Varicella zoster virus is the most significant viral infection
in the INS population and may lead to life-threatening
disease in children receiving Gc and other immunosup-
pressive agents. Dowell et al. performed a retrospective
study to determine the risk of varicella infection associat-
ed with Gc treatment in children with a range of condi-
tions, including INS, by comparing the proportion of
hospitalised cases of severe childhood varicella with con-
comitant Gc treatment to the corresponding proportion in
a sample of children enrolled in a health maintenance
organisation [23]. Among these children, 23.6 % had re-
ceived Gc treatment within 30 days prior to the onset of
their rash compared with 0.2 % of controls, giving an
odds ratio of 178. The authors report that this could in-
crease the varicella-associated risk of mortality from 3.5
deaths per 100,000 cases to 623 deaths per 100,000 cases
[23]. In addition, children receiving immunosuppressive
therapy may present with atypical and severe clinical fea-
tures during episodes of infection with a wide range of
viruses [24, 44–46].
Several viral agents, including respiratory syncytial vi-
rus, influenza virus, parainfluenza virus, VZV and adeno-
virus, have been identified as potential triggers of disease
relapse [47]. In contrast, exposure to measles virus has
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been associated with disease remission [48]. A recent pa-
per demonstrated that Epstein–Barr virus (EBV) DNA in
whole blood and positive IgM serology are more common
in children at the onset of INS than in a non-INS control
group [49]. Based on these results, the authors suggest an
association between the prevalence of EBV and the onset
of INS in children.
Initial treatment of infection
Although S. pneumoniae is the commonest cause of bacte-
rial infection in the child with INS, initial therapy of
suspected infection should include broad-spectrum antibi-
otics until culture and antimicrobial sensitivities are avail-
able. The American Academy of Pediatrics (AAP) state
that in suspected cases of peritonitis, definitive diagnosis
requires the culture of peritoneal fluid [9]. However, in
clinical practice, many cases are treated on an empiric ba-
sis. Tain et al. recommended that combination therapy be
used with children with INS and suspected serious infec-
tion, with vancomycin to cover penicillin-resistant
S. pneumoniae and a third-generation cephalosporin to
cover rare Gram-negative microorganisms [42]. Gorensek
et al. recommended initiating empiric antimicrobial thera-
py in suspected INS-related peritonitis with penicillin and
either an aminoglycoside or broad-spectrum cephalosporin
until culture results are available. If Gram-positive diplo-
cocci are observed in the culture fluid, then penicillin alone
should be satisfactory [38]. The nephrotoxic effects of ami-
noglycoside antibiotics should be considered before the
appropriate therapy is chosen. Aminoglycosides have a
narrow therapeutic window, and therefore diligent moni-
toring of antibiotic levels in blood, followed by dose-
adjustment where necessary, is mandatory for this class
of antimicrobials. Table 1 summarises treatment options
recommended by the Indian Academy of Pediatrics (IAP)
and the Royal Manchester Children’s Hospital (UK) for
antimicrobial treatment according to site of infection.
Prevention of infection
Chemoprophylaxis against bacterial infection
Currently, it is not standard practice to routinely administer
antibiotic prophylaxis in relapse or remission of INS [20].
The AAP states that there are no data supporting the efficacy
of prophylactic penicillin in preventing peritonitis in INS [9].
French guidance recommends prescribing antibiotics only if
infection is evident [20]. However, some centres, including
the Royal Manchester Children’s Hospital (UK) routinely pre-
scribe penicillin prophylaxis (phenoxymethylpenicillin/peni-
cillin V 12.5 mg/kg twice daily) during relapse and stop anti-
biotic therapy when oedema has abated. The reason for the
marked variation in clinical practice may be explained by the
lack of data: no randomised controlled trial (RCT) has ever
been performed to test the efficacy of antibiotic prophylaxis in
INS. However, the existing data bring into question the effi-
cacy of penicillin V in paediatric INS. For example, the liter-
ature contains multiple reports of serious infection occurring
in children with INS receiving penicillin V prophylaxis
[10, 38, 43, 50]. It has been estimated that approximately
110 children with INS would need to be treated for 1 year to
prevent one episode of pneumococcal infection [21]. Children
with INS are at risk of infection from a range of pathogens, so
it is perhaps unsurprising that penicillin monotherapy prophy-
laxis does not appear to confer significant protection, based on
currently available data.
Children with sickle cell disease (SCD) are similarly at
increased risk of developing pneumococcal infection, and ro-
bust evidence exists that penicillin prophylaxis does reduce
infection rates in this population [51]. However, the observa-
tion that the risk of pneumococcal infection in INS is lower
than that in SCD [51] means that the practicalities of designing
a RCT examining the use of chemoprophylaxis in INS repre-
sent a considerable hurdle: 3000 children would be needed to
determine whether prophylactic penicillin reduces the inci-
dence of invasive pneumococcal disease (with only 80 %
power) [21]. The risk of potential drug side-effects and the
Table 1 Management of infections in steroid-sensitive nephrotic syndromea
Infection Common organisms Antimicrobial guidance from Indian
Academy of Pediatrics
Antimicrobial guidance from Royal




Cefotaxime or ceftriaxone (7–10 days);
ampicillin and an aminoglycoside
(7–10 days)
Ceftriaxone (avoid aminoglycoside
due to potential toxicity if possible).
Pneumonia S. pneumonia, Haemophilus
influenzae, Staphylococcus
aureus
Oral: amoxicillin, co-amoxiclav, erythromycin
Parental: ampicillin and an aminoglycoside;
or cefotaxime/ceftriaxone (7–10 days)
Co-amoxiclav or clarithromycin
(if penicillin allergy)
Soft tissue/cellulitis Staphylococci, Group A
streptococci, H. influenzae
Cloxacillin and ceftriaxone (7–10 days),
co-amoxiclav
Flucloxacillin
a Adapted from the publication of the Indian Pediatric Nephrology Group et al. [19], used with the permission of Indian Pediatrics
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development of penicillin-resistant organisms must be bal-
anced against the potential benefit of chemoprophylaxis for
children with INS. Reassuringly, data from the SCD popula-
tion suggest that penicillin prophylaxis does not increase the
rate of colonisation with resistant strains of pneumococcus and
that the rate of drug side-effects is low [52]. The criteria for
use of prophylactic antibiotics in children with INS have tra-
ditionally been an active area of debate. However, the topic
has become less relevant following the introduction of univer-
sal pneumococcal vaccination.
Pneumococcal vaccination
Pneumococcal vaccines are either unconjugated polysaccha-
ride vaccines (e.g. Pneumovax/PPSV23) or protein conjugate
vaccines (PCV). Examples of PCV include Prevnar 13, which
is a tridecavalent vaccine (i.e. containing 13 serotypes of
pneumococcus). In the general population, polysaccharide
vaccines have been shown to be ineffective in children under
2 years of age [53], while PCVs are highly effective in
preventing invasive pneumococcal disease in children in this
population [53, 54]. Universal pneumococcal vaccination is
now standard practice in America and most European coun-
tries, including the UK [55]. In the UK, PCV is administered
to all children at 2, 4 and 12–13 months of age [56]. Children
with INS are also offered an additional single dose of pneu-
mococcal polysaccharide vaccine (PPV) when they are
≥2 years of age [56].
The AAP recommends the administration of pneumococ-
cal vaccines to children with INS (if not already immunised)
[9]. The IAP recommends two to four doses of the conjugate
pneumococcal vaccine for children aged <2 years. For previ-
ously unimmunised children aged 2–5 years, a priming dose
of the conjugate vaccine is recommended, followed 8 weeks
later by a dose of PPSV23. Children older than 5 years require
only a single dose of the polysaccharide vaccine. Revaccina-
tion after 5 years is considered for children under 10 years old
with active INS [19].
To date there has not been a controlled trial with the aim of
examining whether pneumococcal vaccination prevents pneu-
mococcal disease specifically in children with INS. However,
a Cochrane review examined the efficacy of pneumococcal
vaccines in children with SCD, involving five trials with a
total of 547 participants [57]. One trial demonstrated that
polysaccharide vaccine only slightly reduced the risk of infec-
tion in children younger than 3 years of age, while three trials
of conjugate vaccines showed increased antibody response
compared to control groups of all ages. Unfortunately, no data
on clinical outcomes were provided. The authors concluded
that conjugate pneumococcal vaccines should be used in indi-
viduals with SCD. However, caution should be exercised
when extrapolating these findings to the INS population. It
is also important to note that not all pneumococcal serotypes
are included in the vaccines and that antibody levels may
decline during a relapse. Previously vaccinated children
may, therefore, develop pneumococcal peritonitis and sepsis
[19].
Ideally, immunisation is performed when a child is not
currently receiving immunosuppressive therapy. However,
data exist suggesting children on Gc therapy can mount a
sufficient immune response to vaccination. In order to inves-
tigate whether children with INS are capable of adequately
responding to PPV, Spika et al. reported on 27 children with
SSNS and six children with SRNS with 12 age-matched con-
trols, following vaccination with PPV [58]. Antibody re-
sponders were defined as those with at least a twofold increase
in antibody titre after vaccination in addition to an antibody
concentration of >200 ng of anticapsular pneumococcal anti-
body nitrogen per millilitre (ngN/mL) after vaccination. The
post-vaccination mean total antibody concentration for the
control group was 492 ngN/mL, compared to 48 ngN/mL
for the SRNS group (not taking Gc), 639 ngN/mL for the
SSNS group taking Gc and 937 ngN/mL for the SSNS group
not receiving Gc (i.e. higher than controls). Children with
SSNS who were not receiving Gc therapy at the time of vac-
cination had significantly higher antibody titres to five pneu-
mococcal subtypes before vaccination and to seven subtypes
after vaccination compared with control subjects (out of 12
subtypes investigated). Fewer children with SSNS receiving
Gc achieved total antibody concentrations of >200 ngN/mL
against type 19 F compared with children with SSNS not
receiving Gc or with control subjects. Overall, these data sug-
gest that PPV vaccination is sufficiently immunogenic in chil-
dren with SSNS, but not in children with SRNS.
Further data are provided by a French study which demon-
strated that children with INS on high-dose Gc therapy re-
spond to the PPSV23 vaccine [59]. Comparison of the sero-
logical response in 30 children with INS directly after initia-
tion of 60 mg/m2 prednisolone therapy (Group 1) with the
response in 13 children who received the vaccine while in
remission (Group 2) revealed that both groups demonstrated
an approximate tenfold increase in pneumococcal antibody
levels within 1month, but that this had fallen to approximately
three- to fourfold above baseline by 1 year (no difference
between Group 1 and Group 2).
Although decay of pneumococcal antibody levels post-
vaccination is well recognised in healthy children, this decay
seems to be accelerated in children with INS and other CKD
[56]. Spika et al. divided a group of 25 children with SSNS
into a subgroup of non-relapsers and those who had at least
one relapse and observed that the relapsing group had a more
rapid decline in total anticapsular antibody per month than the
non-relapsing group [60]. In a muchmore recent study, Guven
et al. examined IgG antibody levels against specific pneumo-
coccal antigens before and after PPV administration in nine
children with SSNS during remission while off Gc therapy.
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Although a good initial antibody response was found, by
6 months post-vaccination, IgG levels had begun to fall in
six of the nine children, and by the 36th month post-
vaccination only two patients still had high IgG concentra-
tions [61]. Given these data, it is unsurprising that multiple
cases of pneumococcal disease after vaccination have been
reported in the NS literature [38, 62, 63]. An altered IgG-
subclass distribution in children with INS may also contribute
to a sub-optimal response to pneumococcal vaccination.
Influenza vaccination
Children with CKD have a higher risk of influenza virus in-
fection than healthy subjects [56]. Immunosuppressed chil-
dren, including those with INS, occasionally experience se-
vere complications following influenza A infection, but the
disease is mostly mild and self-limiting. An adult study of
25 immunocompromised patients (bone marrow and renal
transplant recipients, and those with haematological malig-
nancies) who developed influenza A infection reported that
only two patients developed serious infections [64]. A study
involving 19 children with INS and ten healthy controls
showed that children with INS mount an adequate response
to influenza vaccine, with the authors reporting no difference
in mean concentration of specific IgG antibodies to influenza
A or protective antibody titres (≥1:40) between the groups at
1 month post-vaccination. These authors followed up eight of
the children for 6 months post-vaccination (none of the con-
trols) and found that these eight children still had protective
antibody titres at the 6 month follow-up visit, and that there
was still a statistically significant difference in the mean con-
centration of specific IgG antibodies compared to the pre-
vaccination concentration [65].
The AAP recommends annual seasonal administration of
influenza vaccine to children with INS [9]. Currently there are
two influenza vaccines available: (1) an inactivated intramus-
cular vaccine and (2) a live attenuated intranasal vaccine. The
live intranasal formulation is contraindicated in children on
high-dose Gc therapy. Current UK guidance suggests that
children receiving either of the vaccines for the first time
should receive a second dose 1 month after administration of
the first [56].
Varicella zoster vaccination
Infection with VZV is associated with significant morbidity
and mortality in children receiving immunosuppressive ther-
apy, including those with INS [23, 66]. The clinician should
also be aware that the diagnosis of varicella may be ob-
scured by atypical or absent skin lesions in the immunocom-
promised child [67]. The AAP recommends varicella vacci-
nation for non-immune children with INS, post-exposure
immunoglobulin for non-immune immunocompromised
children and the consideration of intravenous acyclovir for
immunocompromised children at the onset of varicella skin
lesions [9].
Data from 1997 showed that the varicella vaccine is safe in
children with SSNS, but the authors found that a second vac-
cine dose was necessary before seroconversion was achieved
in four of seven children and therefore recommended a two-
dose vaccine schedule [68]. A U.S. study found that a two-
dose varicella vaccine regimen in 29 children (13 of whom
were receiving alternate-day Gc) produced protective levels
against VZV and that these levels were maintained 2 years
post-vaccination (children were excluded if they had received
cytotoxic immunosuppression in the previous 3 months, or
daily Gc therapy, ciclosporin or tacrolimus within 1 month
of enrolment) [69]. No adverse effects were associated with
vaccination. A study from Turkey examined single-dose VZV
vaccination in 20 children with SSNS and 22 healthy controls
(children with SSNS were either in remission or had already
stopped Gc therapy for at least 6 weeks prior to vaccination)
[70]. Among the 20 children with INS, 85 % seroconverted
8 weeks after vaccination compared to 86 % in the control
group. Two years after vaccination, VZVantibodies were still
detectable in 70 % of children with INS but in only 59 % of
healthy controls. These data support the use of the standard
two-dose VZV vaccination schedule in this population. Cur-
rent UK Department of Health guidance recommends that
VZV vaccine should be given at least 3 months after high-
dose Gc therapy has been discontinued (prednisolone
2 mg/kg/day for at least 1 week, or 1 mg/kg/day for 1 month).
Advice from an immunologist should be obtained regarding
the use of the varicella vaccine in children receiving other
types of immunosuppressive drugs (e.g. cyclophosphamide)
alone or in combination with lower-dose Gc therapy (especial-
ly during the 6 months following discontinuation of immuno-
suppressive therapy) [56]. Finally, some concern has been
raised about the possibility of varicella vaccination causing
INS relapses, but definitive data supporting this hypothesis
are currently lacking. One study reported that among the 20
children with INS, one had a relapse 3 weeks after varicella
vaccination [70]; another study reported relapses in three of
seven children with INS [68]. However, in both studies, the
pattern of relapses in affected children was similar pre- and
post-vaccination, and no causal link could be made.
Management of exposure to VZV in children with INS
When a child with INS is exposed to VZV, knowledge of
immunity status is vital to guide management. Following a
study which demonstrated that self- or parent-reported history
of previous varicella infection is not highly predictive of se-
ropositivity among cohorts of unvaccinated persons born
since 1994 [71], the U.S. Advisory Committee on Immuniza-
tion Practices (ACIP) has reviewed its criteria for patient
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groups considered to have been exposed to VZV [72]. Evi-
dence of immunity to varicella is now limited to the following:
(1) documentation of age-appropriate vaccination with a var-
icella vaccine; (2) laboratory evidence of immunity; (3) birth
in the USA before 1980; (4) diagnosis or verification of a
history of varicella disease or herpes zoster by a healthcare
provider. When a VZV naïve (according to the above criteria)
immunosuppressed child is exposed to VZV, passive
immunoprophylaxis and/or aciclovir should be considered.
Significant exposure to varicella may be defined as Bresiding
in the same household, face-to-face indoor play for more than
1 h and hospital contact with an infectious individual (same 2-
to 4-bed room or in adjacent beds or a visit in room by conta-
gious person for more than 1 h)^ [73]. The two choices for
passive immunisation against varicella infection are varicella
zoster immunoglobulin (VZIG) and a purified human varicel-
la zoster immune globulin prepared from plasma containing
high levels of anti-varicella IgG (VariZIG).
Children should receive passive varicella immunisation as
soon as possible after exposure [74], but there are some data
suggesting that the incidence of varicella is comparable
among children who receive VZIG within 4 days of exposure
and those who receive it >4 days (up to 10 days) after expo-
sure and that attenuation of the disease might be achievedwith
administration of VZIG up to 10 days after exposure [74].
VZIG is given by intramuscular (IM) injection, but children
with bleeding disorders who cannot receive IM doses should
be given intravenous normal immunoglobulin. Studies from
the 1970s demonstrated that VZIG favourably modified dis-
ease severity and reduced susceptibility to VZV in immuno-
compromised children following household exposure
[75, 76]. A further study found that VZIG provided protection
against severe infection in immunocompromised children fol-
lowing varicella exposure although 60 % of 81 recipients of
VZIG still experienced clinical VZV infection [77].
Evidence supporting the use of aciclovir following expo-
sure to varicella comes from a 1993 Japanese study [78]. In
this study, oral aciclovir was given to 25 exposed infants and
children for 7 days, beginning 7–9 days post-exposure. At the
end of the study period, clinical features of the 25 exposed
infants who received aciclovir were compared with 25 age-
matched exposed patients who did not receive aciclovir. Only
16 % of the subjects treated with aciclovir developed the dis-
ease, while all 25 individuals in the control group developed
VZV infection. The incidence of fever and the severity of skin
rashes were significantly lower in the subjects receiving acy-
clovir than in the control group. A separate study examined
the efficacy of post-exposure aciclovir prophylaxis in children
receiving Gc treatment post-renal transplant or for INS [79].
Group 1 received oral aciclovir 7 days after exposure for
7 days. Both groups additionally received VZIG. No child in
Group 1 (n=8) developed chickenpox compared to 25 % of
the children in Group 2. However, the study size was too small
for the authors to draw any definitive conclusions. The IAP
recommends that children who develop VZV infection should
receive intravenous aciclovir (1500 mg/m2/day in 3 divided
doses) or oral aciclovir (80 mg/kg/day in 4 divided doses) for
7–10 days. The guidelines also recommend that the dose of
prednisolone should be tapered to 0.5 mg/kg/day or lower
during the infection [19].
Measles infection
Measles can be a devastating illness in immunosuppressed
children with INS [24]. It is important to document the mea-
sles status for all children with INS (measles immunisation is a
routine part of childhood vaccination in the UK, Europe and
USA). Measles-specific immunoglobulin therapy should be
considered if a non-immune children with INS comes into
contact with measles (aciclovir is not effective).
Adrenal insufficiency
During periods of infection, the clinician should pay careful
attention to the dose of Gc prescribed: infection is a significant
stressor and failure to increase Gc supplementation during
these periods is a significant cause of morbidity and mortality
due to acute adrenal insufficiency [80]. In a study evaluating
rates of adrenal suppression in ten children with acute lym-
phoblastic leukaemia receiving a 4-week course of Gc therapy
(oral dexamethasone 6 mg/m2 per day/approximately
0.2 mg/kg per day, divided into two daily doses), all ten chil-
dren had normal adrenal function before commencing Gc
treatment and an insufficient adrenal response 24 h after com-
pleting therapy (evaluated using the short Synacthen test). Of
these ten children, three did not regain normal adrenal func-
tion until 8 weeks after discontinuation of Gc therapy [81]. In
another study involving children with INS, those receiving
long-term alternate-day Gc treatment (mean prednisolone
dose 0.40 mg/kg) were found to be at risk of developing ad-
renal suppression (again evaluated using a short Synacthen
test), and those with a suboptimal cortisol response were at
greater risk of disease relapse [82]. Children with INS on
prolonged prednisolone also remain at risk of adrenal insuffi-
ciency until at least 9 months after discontinuation of Gc ther-
apy [83].
Controversy exists regarding the level of symptomatic in-
fection that requires increases in Gc dose. Guidance from the
Pediatric Endocrine Society suggests uncomplicated viral ill-
ness and upper respiratory tract infections with sore throat,
rhinorrhoea, otitis media and/or low-grade fever may not re-
quire treatment with a stress-dose steroid regimen if the child
otherwise appears well. Conversely, illness accompanied by
fever of ≥38 °C should be accompanied by increased Gc doses
[80]. The degree to which doses should be increased is also
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under debate, with recommendations varying between two-
and tenfold the ‘maintenance rate’ [80]. If parenteral Gc is
required due to inability to tolerate oral maintenance therapy,
hydrocortisone is the preferred agent due to its additional min-
eralocorticoid activity [80]. Recommendations specific to INS
are extremely limited, but the IAP recommends that children
who have received high-dose Gc therapy within the last 2
years require supplemental doses of Gc during periods of se-
rious infection [19]. The guidance does not formally define
‘high-dose steroids’ or provide guidance as to what steroid
supplementation should entail. However, the UK Department
of Health defines ‘high-dose’ Gc therapy as prednisolone
2 mg/kg/day for at least 1 week or, alternatively, 1 mg/kg/
day for 1 month [56].
Thromboembolic disease
Thromboembolic disease (TED) is the second leading cause
ofmortality in the nephrotic child [2, 84]. A large review using
data from the U.S. National Discharge Survey found that in
the 18- to 39-year-old group, the relative risk of deep vein
thrombosis in INS patients, compared to patients without
INS, was 6.81 (no data was provided for the paediatric popu-
lation) [85]. INS-associated thromboembolism is much more
common in adults (20–52 %) [86–89] than in children (child-
hood prevalence of 2–13 %) [31, 90–99].
A study involving 326 children with INS and a median
follow-up time of 3.7 years reported that 9.2 % of the patient
cohort experienced at least one episode of TED. Deep venous
thrombosis was the most common TED event (76 %) and was
frequently associated with the use of a central venous catheter
(45 % of deep venous thrombosis events). Unfortunately, it is
unclear whether the presence of a central venous catheter was
simply a marker of disease severity, or whether the presence of
the catheter itself conferred increased risk for TED [98]. These
results were similar to those reported by Lilova et al., who
found that TED in children with INS was predominantly ve-
nous (81 % vs. 19 % arterial), with the most commonly af-
fected vessels being the deep leg veins, followed by the infe-
rior vena cava [96]. Although arterial thrombosis occurs less
frequently than venous thrombosis in INS, it may cause dev-
astating cerebral, abdominal, peripheral and renal infarction.
Suri et al. reported on seven children with INS who experi-
enced central nervous arterial infarcts and two children with
thrombosis of peripheral arteries [100]. The children with in-
tracranial arterial thrombosis presented with either an acute
stoke/hemiparesis-like event or seizures, while the remaining
two children experienced involvement of either the posterior
tibial or brachial artery, leading to progressive gangrene. TED
in children with INS generally occurs early in the disease
course, with a median time from diagnosis to the first TED
event of 71 days [98]. Clinicians should be alert to the possi-
bility of TED soon after the initial diagnosis of INS.
Pathophysiology
The underlying reasons for high TED rates in INS are poorly
understood, but they are likely to be multifactorial [99]. Gen-
eral background risk factors, such as the presence of known
thrombophilic genetic mutations (e.g. congenital antithrombin
deficiency) or the placement of central venous catheters, may
place the child with INS at higher risk for TED [101]. Sahin
et al. provide adult data suggesting that coexistence of
inherited thrombophilia in NS may increase the risk for
TED. In this study of 51 newly diagnosed INS patients, six
(11.8 %) had TED at time of diagnosis (4 symptomatic, 2
subclinical), all of whom carried mutations for either the
pro-thrombotic Factor V Leiden, prothrombin or methylene-
tetrahydrofolate gene [102]. The observation that the fibrin
clot formed by nephrotic serum has an alteredmolecular struc-
ture and is more resistant to fibrinolysis compared to fibrin
clots from healthy controls is another plausible explanation of
the thrombotic tendency in children with INS [103].
Another frequently cited reason for increased TED rates in
children with INS is urinary loss of key regulators of
haemostasis during relapse. Unfortunately, data directly ex-
amining the link between such derangement and TED risk
are scarce [99]. However, it is clear that the children with
INS do have an altered haemostatic milieu. For example, plas-
ma concentrations of higher molecular weight procoagulant
proteins, such as factor V and factor VIII, are elevated in the
nephrotic state [94]. Additionally, urinary loss of the lower
molecular weight (anticoagulant) protein antithrombin (AT)
may shift children with INS to a prothrombotic state [94]. A
raised platelet count is an extremely common finding in INS
[99]; however, it is unclear whether the reactive
thrombocytosis seen in INS actually increases the risk for
TED [104]. Eneman et al. recently demonstrated that urinary
losses and resultant plasma deficiency of an inhibitor of
megakaryopoiesis and platelet aggregability, pituitary adenyl-
ate cyclase-activating polypeptide (PACAP), may play a role
in the pathogenesis of platelet dysfunction in INS [105].
Ideally, a biomarker for predicting TED risk for children
with INS would be available to clinicians. Although this re-
mains a future goal, a recent study from China has shown that
adult INS patients with TED had higher levels of two markers
of endothelial injury, namely, circulating endothelial cells and
von Willebrand factor, compared to adult patients without
TED disease and healthy controls [106].
Diagnosis and investigations
Signs and symptoms of TED include a painful, swollen ex-
tremity in cases of venous thrombosis and/or respiratory
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compromise in cases of pulmonary embolism (PE) [107]. In
addition, headache or visual disturbance may reflect an under-
lying sagittal sinus thrombosis. Any suspicion of clinical TED
should prompt urgent imaging to confirm the diagnosis.
Computerised tomography pulmonary angiography (CTPA)
is the modality of choice for patients with clinically suspected
PE [108]. Doppler compression ultrasonography is used as
first-line imaging for suspected venous thrombosis, but if im-
ages are suboptimal, magnetic resonance venography can be
utilised [107].
Data are limited to help decide whether children with INS
should be routinely and regularly imaged (irrespective of clin-
ical signs/symptoms). Hoyer et al. imaged 26 children with
SSNS in the acute phase of a relapse but without symptoms of
TED using combined scintigraphic pulmonary ventilation and
perfusion scans and found signs consistent with PE in 28% of
children and residual changes consistent with previous PE in
39 % [92]. CTPA is now considered superior to ventilation–
perfusion scans for the diagnosis of PE due to similar sensi-
tivity but improved specificity [108]. A more recent CTPA
study found similarly high rates of subclinical PE in NS chil-
dren (28 %) [109]. In summary, a significant proportion of
TED in INS is subclinical, and the medical team should al-
ways be alert to the possibility of TED-related complications
in children with INS.
Standard laboratory tests in the child with proven or
suspected TED should include platelet count, prothrombin
time, activated partial thromboplastin time, thrombin time,
fibrinogen and quantitative D-dimers. Measurement of AT
may be warranted in severe cases or in children not
responding adequately to anticoagulant therapy (see below)
[107].
Few studies have been conducted to determine the con-
tribution of genetic prothombotic defects to the overall risk
for TED in INS [100]. Fabri et al. tested 53 children with
INS for thrombophilic genetic defects and reported that
TED events occurred in six of these 53 children. An
inherited risk factor was identified in seven children, none
of whom experienced a TED event [110]. American Col-
lege of Chest Physicians Evidence-Based Clinical Practice
(ACCP) Guidelines for Children do not include the pres-
ence of inherited thrombophilia to guide the duration of
antithrombotic therapy, and there are no evidence-based
guidelines for thromboprophylaxis in children with
thrombophilia. Therefore, genetic testing is not routinely
endorsed outside of a research setting [107, 111, 112]. The
AAP recommends the evaluation of children with INS and
TED for an underlying hypercoagulopathy but does not
specify whether this should involve genetic testing [9].
Although robust evidence supporting the introduction of
routine screening for genetic causes of thrombophilia in
INS is lacking [113], some centres support the use of ge-
netic testing as these children may benefit from close
follow-up and longer duration of treatment should a TED
event occur [110, 114].
Primary prevention
The decision to begin prophylactic therapy for any medical
condition rests on the balance between potential side-effects
of the prophylactic therapeutic strategy and the benefit of dis-
ease prevention. Clinicians cannot make an appropriately in-
formed decision regarding the use of prophylaxis to prevent
INS-related TED because no large, randomised trials to
determine the safety and efficacy of this approach have
been performed to date. However, it is unlikely that
pharmacoprophylaxis for all children with INS will be a
desirable st ra tegy. I t has been est imated that i f
pharmacoprophylaxis were to be universally applied, 75–
97 % of children with INS would receive unnecessary
anticoagulation and potentially suffer subsequent
anticoagulation-related complications, such as bleeding
[107]. Although some authors have proposed the use of pro-
phylactic aspirin in this patient group [115], clinicians should
be aware of the potential risk of acute kidney injury associated
with nonsteroidal anti-inflammatory medications [116]. The
IAP states that there is no role for prophylactic treatment with
anticoagulants in children with INS (even during periods of
hypoalbuminaemia and oedema) [19]. Guidelines from
France acknowledge that no consensus regarding TED prima-
ry prophylaxis exists. However, they suggest that children
with a more severe disease phenotype (albumin <20 g/L; fi-
brinogen >6 g/L; antithrombin III <70 %; D-dimer >1000 ng/
mL) may be considered for prophylaxis with aspirin or low
molecular weight heparin (LMWH). Finally, a retrospective
cohort study has suggested that statin therapy may lower the
risk for venous thromboembolism (VTE) in adults with INS,
but more robust data are needed [117]. Recommendations to
guide use of primary prevention strategies for INS await de-
finitive trials. The AAP recommends that during periods of
disease activity and increased thromboembolic risk, children
should be encouraged to continue physical activity and avoid
prolonged bed rest [9].
Treatment
Once TED has developed, prompt anticoagulation should be
initiated. The ACCP guidelines state that a child with a first
VTE should receive an initial minimum 3- to 6-month course
of anticoagulation [111]. In children, this is typically initiated
with LMWH. Published weight- and age-based nomograms
are available for LMWH dosing in children [111, 118]. War-
farin treatment may begin concurrently for longer term
anticoagulation, and as warfarin is cleared hepatically, renal
dose-adjustments are generally not required. In contrast, many
heparin compounds are cleared by renal excretion and,
Pediatr Nephrol (2016) 31:1383–1402 1391
therefore, special attention should be paid to any sign of renal
dysfunction and the dose altered accordingly if necessary [99].
The mechanism of action of heparins is dependent on AT
and, very rarely, AT supplementation may be necessary to
achieve an adequate anticoagulant effect. Some isolated re-
ports exist of clinicians administering fresh frozen plasma to
correct for the expected AT deficiency, irrespective of actual
AT levels, but this is not routine practice [96]. No published
INS-specific optimal AT target levels exist, although a small
case series shows the effective use of recombinant AT in adults
with congenital AT during the peri-operative period [119]. In
children with INS, titrating LMWH therapy to anti-Xa levels
can result in more effective anticoagulation [120]. As yet no
data regarding the use of new oral anticoagulants exist specif-
ically for children with INS, although this is a promising pos-
sibility for future management [121].
Thrombolytic therapy should be considered for life-, or-
gan-, or limb-threatening TED [111, 122, 123]. One example
of organ-threatening TED is bilateral renal venous thrombo-
sis. Consideration of the associated bleeding risk should be
made before therapy with a thrombolytic agent is commenced.
This is particularly important for premature neonates in whom
TED is more common. A recent trial involving 30 neonates
treated with LMWH found a poor therapeutic response to
recommended doses based on measured anti-Xa levels, and
the authors suggest higher initial doses may be required to
achieve therapeutic anticoagulation [124]. No robust data on
the safety and efficacy of thrombolytic therapy in children
with INS exist, but effective and safe use of streptokinase
[96, 125] and tissue plasminogen activator [126] for severe
TED has been documented in children with INS.
Oedema
Oedema is a cardinal feature of INS and may lead to respira-
tory and functional constraints (such as impaired vision be-
cause of swollen eye lids and reduced mobility because of
severe lower limb oedema) [9, 127]. Traditional teaching sug-
gests that oedema is associated with intravascular
hypovolaemia, which may lead to acute, pre-renal, renal fail-
ure. Signs and symptoms associated with this oedematous
hypovolaemic state include tachycardia, abdominal pain, cool
peripheries, oliguria and hypotension [128]. However, chil-
dren with oedema associated with INS do not universally ex-
perience intravascular volume depletion; in fact, some studies
suggest that children with INS may have normal or even in-
creased intravascular pressure [129, 130].
Two competing theories to explain INS-associated oedema
have been proposed: the ‘underfill’ [131] hypothesis and the
‘overfill’ hypothesis [132–134]. The underfill hypothesis sug-
gests that INS-associated proteinuria and associated
hypoproteinaemia leads to reduced plasma colloid osmotic
pressure, hypovolaemia and stimulation of the renin–angio-
tensin–aldosterone system, resulting in salt and water reten-
tion. Supportive data do exist which suggest that reduced in-
travascular volume, reduced glomerular filtration rate (GFR)
and increased renin and aldosterone levels are features of INS
[135].
Observations that plasma renin activity and reduced intra-
vascular pressure are not universal characteristics of INS led
to the overfill theory being proposed, with INS-associated
oedema being primarily a defect in sodium excretion [133].
The overfill theory has several critics and is not universally
accepted [26, 136]. However, it is clear that the standard
(‘underfill’) doctrine of hypovolaemia and salt retention
resulting from hypoproteinaemia is an oversimplification.
Vande Walle et al. demonstrated that children with significant
proteinuria can present both with, and without, hypovolaemic
symptoms and laboratory signs, despite equally severe
hypoproteinaemia and that sodium retention precedes
hypoproteinaemia [128].
Management
Mild oedema can often be managed conservatively with fluid
restriction to two-thirds of maintenance and dietary sodium
restriction to <2 mEq/kg/day [137]. Strict monitoring of body
weight to assess the efficacy of these interventions is required.
However, severe, symptomatic oedema may require pharma-
cological management, including loop diuretics, thiazide di-
uretic and/or 20–25 % albumin solution. When the use of a
pharmacological agent is considered, it is necessary to differ-
entiate ‘underfill’ (i.e. intravascular volume depletion) and
‘overfill’ (i.e. primary renal sodium retention) oedema [138].
Clinically it is often difficult to differentiate between these two
states. However, Schrier et al. provide a number of useful
indicators which would suggest an underfilled patient: (1)
the presence of postural hypotension, (2) a history of MCD,
(3) a serum albumin level of <20 g/L and (4) an estimated
GFR (eGFR) of >75 % of normal. In contrast, hypertension,
a serum albumin level of >20 g/L and an eGFR of <50 % of
normal would suggest an overfilled patient [136].
Urinary indices are also useful in determining the volume
status in children with nephrotic oedema. A study from 2009
examined the use of fractional excretion of sodium (FeNa) in
30 children with INS admitted to hospital with oedema (pa-
tients on diuretics or receiving immunosuppressive therapy on
admission were excluded). The authors reported a FeNa value
of 0.2 % could distinguish patients with intravascular volume
contraction (FeNa <0.2 %) from those with intravascular vol-
ume expansion (FeNa >0.2 %). In this study, ten of the 11
patients with FeNa values of >0.2 % were successfully treated
with diuretic therapy alone (intravenous furosemide and oral
spironolactone) [137].
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Some centres also advocate the use of the quotient of
urine potassium and urine sodium + potassium [UK/(UNa+
K) × 100 %], which is an indicator for sodium/ potassium
exchange at the distal nephron [139]. Vande Walle et al.
suggest that if a low FeNa and a Uk/(UNa+K) ratio of
>60 % are measured, an albumin infusion can safely be
administered if clinically required. In contrast, patients
with a normal FeNa and a Uk/(UNa+K) ratio of <60 % with
incapacitating oedema should be treated with diuretics
[140]. An important point to consider when obtaining urine
for electrolyte analysis is that children should be on normal
salt and water intake [138]. Additionally, diuretics,
angiotensin-converting enzyme inhibitors (ACE-I) and an-
giotensin receptor blockers (ARB) may interfere with urine
indices and hence should not be used before the urine indi-
ces have been tested or, alternatively, diuretics should be
discontinued for at least 8 h. Kapur et al. presented data
showing that diuretic therapy alone is safe and effective
for severe oedema in overfilled children with INS, while
underfilled patients may require both albumin and diuretics
[137]. Diuretic use in underfilled patients (if used) requires
diligent monitoring of the renal and systemic haemody-
namic status to ensure that intravascular volume depletion
is not exacerbated. Lower dose therapy is indicated initial-
ly. Overfilled patients may benefit from more aggressive
diuretic therapy [141]. In mildly oedematous patients with
a normal eGFR, many clinicians favour an oral thiazide
diuretic as first-line therapy [141]. With severe oedema,
intravenous loop diuretics may be more effective [142].
Loop diuretics block the sodium chloride co-transporter in
the thick ascending limb of the loop of Henle [143]. Resis-
tance to loop diuretics can occur and may partly be due to
diuretic-induced negative sodium balance activating ‘sodi-
um-retaining’ homeostatic mechanisms (e.g. sympathetic ner-
vous system, renin–angiotensin–aldosterone system), thus
functionally antagonising the intended diuretic effect. Concur-
rent use of a thiazide or amiloride may help under these cir-
cumstances [141]. However, poor drug compliance and die-
tary salt intake should first be excluded as apparent causes of
loop diuretic-resistance. A trial of intravenous furosemide
may also overcome apparent loop diuretic-resistance as it cir-
cumvents the poor bioavailability associated with an
oedematous bowel wall.
Loop diuretics have a short duration of action (typically
6 h) and must be administered at least twice daily. Furose-
mide is a very commonly used loop diuretic, and one study
in children with INS showed that 1 mg/kg of intravenous
furosemide was twofold more effective than 2 mg/kg of
oral furosemide [142]. If combination ‘loop and thiazide’
or ‘loop and thiazide-like (e.g. metolazone)’ diuretic ther-
apy is considered necessary, careful monitoring to avoid
hypokalaemia and alkalosis is required. The addition of
amiloride or the mineralocorticoid receptor antagonist
spironolactone to loop diuretic therapy can minimise
hypokalaemia, although the absolute diuretic effect of
these drugs is debatable [144, 145].
Failure of diuretic therapy in the oedematous child with
INS may necessitate administration of intravenous loop
diuretic therapy in conjunction with 20–25 % albumin so-
lution. However, this treatment modality is not without
risks: Haws et al. showed that although albumin and di-
uretic therapy results in fluid removal and weight loss in
children with INS, the effect is transient unless remission
of proteinuria occurs and it can be associated with serious
adverse effects such as respiratory failure and congestive
heart failure [146]. Reid et al. described three children with
INS who required intensive care for life-threatening fluid
overload and pulmonary oedema after receiving an exces-
sive dose or a too rapid infusion of 20 % albumin solution,
leading these authors to recommend 20 % albumin at a
dose of 1 g/kg ideal body weight be given over 4 hours
when warranted [147]. Albumin infusions can also be as-
sociated with allergic reactions, including anaphylaxis
[148].
Careful assessment of a patient’s intravascular volume sta-
tus is vital before commencing an albumin infusion. When an
albumin infusion is required, fluid volumes should be calcu-
lated based on an estimated ‘dry’ weight rather than an
oedematous weight. Albumin solution is likely to be more
beneficial in children with INS who are underfilled in associ-
ation with severe hypoalbuminaemia (<20 g/L). In contrast,
the risk–benefit ratio is likely to be unfavourable in the child
with INS who is oliguric or who has significantly reduced
eGFR (due to the risk of pulmonary oedema); or in the child
who is overfilled, as this may exacerbate the hypervolaemia
and contribute to worsening systemic hypertension and pul-
monary oedema [141].
Some data have implicated stimulation of arginine vaso-
pressin (AVP) from the pituitary gland as an important fac-
tor in oedema-formation in a rodent model of NS and adult
NS patients [149, 150]. A case report documents the effec-
tive use of a selective oral vasopressin V2 receptor antag-
onist (tolvaptan) to treat a girl with NS-associated oedema,
refractory to treatment with diuretics and albumin solution
[127]. Several studies suggest that aberrant filtration of the
urinary serine protease precursor plasminogen during pe-
riods of proteinuria, followed by conversion to its active
form, plasmin, by renal tubular urokinase-type plasmino-
gen activator causes activation of the epithelial sodium
channel (ENaC) in the collecting duct [151, 152]. This ob-
servation may explain the inappropriate sodium retention
often associated with INS and identifies urine serine prote-
ase inhibitors as another potential therapeutic target for
treatment of oedema in INS. Further data on the use of
these agents are required. The current IAP guidance on
the treatment of oedema in INS is summarised in Fig. 1.
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Dyslipidaemia
Dyslipidaemia is a common feature of INS. Zilleruelo et al.
studied 59 children with INS and found that serum total
cholesterol and triglyceride levels were greater than or
equal to the 95th percentile for age and sex in all children
with minimal change NS (MCNS) in relapse and in chil-
dren with non-MCNS with persistent nephrotic range pro-
teinuria. Significantly decreased levels of the cardio-
protective high-density lipoprotein (HDL) and persistent
proteinuria were found in children with non-MCNS [153].
The pathophysiology is incompletely understood but may
include increased hepatic 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase and acyl-coenzyme
A-cholesterol acyltransferase activities or reduced lipopro-
tein lipase activity [154–156]. A role for the podocyte-
secreted INS-triggering circulating factor angiopoietin-
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Fig. 1 Modified Indian Academy
of Paediatrics guidelines for the
treatment of oedema in INS.
Adapted from [19], used with
permission from Indian
Pediatrics. Patients should only
receive diuretic therapy or
albumin infusions under close
clinical supervision. Fluid
volumes should be calculated on
an estimated ‘dry’ weight rather
than an oedematous weight.
Electrolyte levels should be
monitored in all patients receiving
diuretics, and potassium
supplements/spironolactone
started when necessary. FeNa
Fractional excretion of sodium,
UK/(UNa+K) quotient of urine
potassium and urine sodium plus
potassium, I.V. intravenous, B.P.
blood pressure, H.A.S. human
albumin solution, P.I.C.U
paediatric intensive care unit
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In children with INS, dyslipidaemia rapidly normalises fol-
lowing the disappearance of proteinuria [158]. It is unlikely
that intermittent dyslipidaemia in childhood INS has any long-
term consequences, although there is some anecdotal evidence
of myocardial infarction and documented atherosclerosis in
children with INS [159, 160]. As children with INS some-
times have several cardiovascular disease (CVD) risk factors
in addition to dyslipidaemia (e.g. hypertension, Gc-induced
obesity, insulin resistance), the potential risk of dyslipidaemia
cannot be discounted on current evidence. INS in adults is
associated with atherosclerosis and an increased risk for
CVD [161]. However, in a study of 62 adults who had INS
as children, the patients were found not to be increased risk for
CVD mortality or morbidity compared to the general popula-
tion [162].
Treatment with HMG-CoA reductase inhibitors (e.g. sim-
vastatin, atorvastatin) has demonstrated a beneficial effect on
dyslipidaemia in adult INS patients, but no data are available
regarding the effect on long-term CVD health outcomes for
this population [163, 164]. A meta-analysis of HMG-CoA
reductase inhibitor use in the paediatric familial hypercholes-
terolaemia population has demonstrated short-term safety and
efficacy [165]. HMG-CoA reductase inhibition blocks intra-
cellular cholesterol synthesis, and the effects this has on cell
growth, cell membrane and hormone synthesis are unknown.
This is of particular concern for the pre-pubertal child. In rats,
simvastatin and lovastatin were found to cause growth retar-
dation and severe myopathy, although pravastatin did not
show these effects [166]. RCTs involving HMG-CoA reduc-
tase inhibitors in the childhood INS population are lacking.
When lipid-lowering agents are being considered in pre-
pubertal children with INS, fibrate therapy may be a safer
option than the use of HMG-CoA reductase inhibitors [158].
Dietary modification has been proposed as a potential treat-
ment option to reduce the risk of CVD in adult NS patients. A
vegan, low-protein diet [167] and vegetarian, low-protein diet
[168] in adult INS patients was found to reduce serum choles-
terol, but had no effect on triglyceride levels. Interestingly, one
study found that treatment of 11 initially SRNS children with
Gc therapy and low-density lipoprotein apheresis resulted in
complete remission in five children and partial remission in
two children [169]. The AAP recommends a low-fat diet in
children with INS, as well as consideration of low-density
lipoprotein cholesterol-lowering drug therapy, when fasting
low-density lipoprotein cholesterol levels are persistently be-
tween >160 and 190 mg/dL (4.1– 4.9 mmol/L) [9].
Obesity and growth
Two major side-effects of long-term, high-dose prednisolone
treatment are growth impairment [170] and obesity [171]. A
study of 80 children with SSNS examined 5–24 years after the
initial diagnosis found that total Gc dose only correlated
weakly with height standard deviation score (HSDS); there
was also no correlation detected when post-pubertal children
were studied separately [172]. Saha et al. studied 21 prepuber-
tal children with steroid-dependent NS (SDNS) or frequently-
relapsing NS before and during repeated oral Gc therapy and
found that these children grew normally for their age before
the onset of disease and that growth remained after disease
onset despite Gc therapy [173]. Emma et al. conducted a study
involving 42 children with SDNS and 14 children with
frequently-relapsing NS and examined longitudinal height
measurements over a mean period of 11.7 years. These au-
thors found that during the pre-pubertal period, children lost
0.49 HSDS, although partial catch-up growth occurred after
Gc withdrawal. The only statistically significant predictors of
long-term outcome were mean duration of Gc therapy and
average cumulative dose of Gc therapy [174]. A study of 29
boys and 12 girls with SSNS found that HSDS worsened
significantly with chronological age for both boys and girls
and that there was a significant negative correlation between
the change in HSDS and duration of Gc treatment in boys, but
not girls [175]. Berns et al. observed 60 children with INS for
a minimum of 10 years from disease onset. Those children
treated with Gc alone were −0.93 SD below the mean for
height at last follow-up; in contrast, treatment with the Gc-
sparing agent cyclophosphamide was associated with an in-
crease in HSDS from −0.84 to −0.28 [176]. A similar obser-
vation was made in a study measuring the growth velocity of
12 children prior to and following treatment with either cyclo-
phosphamide or chlorambucil, and alternate-day Gc therapy.
The growth rate before the introduction of the alkylating
agents was 4.3 cm/year, but this increased to 8.7 cm/year after
therapy [177]. Hung et al. also found Gc therapy impaired
linear growth in a dose-dependent manner but that combined
administration of cyclophosphamide or chlorambucil reduced
this effect [178].
A 2010 study has given important insight into the effects of
prednisolone treatment specific to children with INS.
Simmonds et al. studied the growth of 41 children with SDNS
over a mean follow-up period of 4.2 years [179]. Overall,
prednisolone treatment up to cumulative mean doses of pred-
nisolone of 0.75 mg/kg/day was shown to not adversely affect
HSDS. In those taking cumulative mean doses of
>0.75 mg/kg/day, some decline in height SDS was seen dur-
ing periods of higher steroid use, but periods on lower steroid
doses allowed for adequate catch-up growth.
Evidence showing that steroid-sparing strategies may re-
duce obesity in children with INS comes from a study which
demonstrated that following a reduction in prednisolone dose,
obesity persisted in only two out of 13 initially obese children
[50]. It should also be noted that no increased obesity rates
[measured by body mass index (BMI)] were observed in adult
patients who had experienced INS as children, and no
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correlation was found between weight in adulthood and cu-
mulative Gc dose [11]. There is a paucity of data on the role of
exercise in INS, but French guidance recommends that regular
exercise should be undertaken. Monitoring of linear growth
and BMI for children with INS is mandatory, and appropriate
dietary counselling should be offered [9].
Fracture risk
Children with NS may be at risk from steroid-induced osteo-
porosis and osteomalacia due to decreased 25-hydroxy-
vitamin D levels secondary to urinary loss of vitamin D bind-
ing protein, potentially placing them at an increased risk of
bone fractures [180, 181].
Gulati et al. prospectively studied 100 children with NS
and found that 22 % had osteoporosis [quantitatively
expressed as a bone mineral density (BMD) value evaluated
by dual-energy X-linked absorptiometry (DEXA) of the lum-
bar spine] [182]. Additionally, a significant correlation was
found between a lower BMD score and a greater cumulative
steroid dose. Hegarty et al. also showed a significant reduction
in forearm trabecular BMD in adults who suffered childhood
INS [183]. In contrast, Leonard et al. examined 60 children
with INS and 195 controls and found no deficits in spine or
whole body bonemineral content [184]. It has not been shown
that reduced BMD in children with INS results in an increased
fracture rate. However, adults taking a prednisolone dose of
≥7.5 mg/day for either treatment of asthma or rheumatoid
arthritis were found to have a twofold higher risk of experienc-
ing a fracture [185].
A prospective study examined 100 children with INS over
a mean of 1.5 years with serial DEXA imaging. Children who
received supplemental calcium and vitamin D3 from study
onset showed improved BMD scores compared to those not
receiving supplementation [186]. The IAP recommends that
children with INS receiving prolonged Gc therapy
(>3 months) should receive daily supplements of oral calcium
(250–500 mg) and vitamin D (125–250 IU) [19]. However,
further trials are necessary to assess the role of calcium and
vitamin D supplementation and to determine whether this
therapy affects fracture risk in children with NS.
Thyroid disease
Clinicians should be aware of thyroid disease in INS. Chil-
dren with INS may experience low T4 and T3 levels sec-
ondary to urinary loss of thyroxine-binding globulin. How-
ever, serum levels of free throxine (FT4) and thyroid-
stimulating hormone (TSH) are usually normal, and these
children are considered to be euthyroid [187, 188]. Chil-
dren with SRNS seem to have a higher risk of developing
hypothyroidism than children with SSNS [188]. Children
with INS have a state of mild/subclinical hypothyroidism
during proteinuria although they are clinically euthyroid.
This temporary state improves with remission and needs no
treatment [189]. Ito et al. recommend that serum thyroid
hormone concentrations be measured in children with INS
and severe proteinuria persisting for >3 weeks despite Gc
therapy and that thyroid replacement therapy, in addition to
Gc, be provided to children with INS and evidence of
moderate or severe hypothyroidism [190].
Hypertension
Cardiovascular disease is the leading cause of death in the
adult dialysis and renal transplant population [191]. The pae-
diatric nephrologist should be alert to CVD risk factors in
children with chronic renal disease and attempt to minimise
these risks as early as possible. Hypertension is a major CVD
risk factor, and a study of 57 children with INS found a prev-
alence of hypertension (defined as blood pressure >95th per-
centile for age) of 19 % [192]. The AAP recommend a low-
salt diet, exercise and weight reduction if obesity is present. If
blood pressure exceeds the 90th percentile of normal, anti-
hypertensive pharmacological management in the form of
ACE-I or ARB should be initiated.
Table 2 Summary of treatment
strategies in different phases of
idiopathic nephrotic syndrome





Prophylactic antibiotics ✘ ✘ ✘
Pneumococcal vaccine ✘ ✘ (ideally) ✓
Influenza vaccine ✘ ✘ ✓
Varicella vaccine ✘ ✘ ✓
Thromboprophylaxis ✘ ✘ ✘
Consideration of fluid restriction/
diuretics/ albumin infusions
✓ ✘ ✘
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Persistent nephrosis
For children with SRNS, blockade of the renin–angiotensin
systemwith either an ACE-I or angiotensin II receptor blocker
ARB is recommended [9, 14]. These agents should also be
considered in SDNS or frequently-relapsing NS. Two RCTs
using the ACE-I enalapril and fosinopril have demonstrated a
reduction in proteinuria in children with SRNS [193, 194]. In
children with renal failure due to INS refractory to pharmaco-
logical management, bilateral nephrectomy by renal ablation
or renal artery embolisation may be performed [195]. This
procedure is also important in the pre-transplant setting to
reduce thrombotic risks of the nephrotic state at renal
transplantation.
Conclusion
Children with INS generally have a favourable long-term out-
come. A challenge for clinicians is to treat the immediate
problems of proteinuria, altered fluid balance and infection,
while minimising the long-term risk to health. A summary of
major supportive therapies for INS is given in Table 2.
NS is a complex disorder and more research needs to be
performed to ensure informedmanagement decisions are made.
Infection should be treated promptly with broad-spectrum an-
tibiotics in the nephrotic child. However, the role of antibiotic
prophylaxis is still unclear, and vital data on the efficacy or
otherwise of the pneumococcal vaccine in children with INS
are lacking. Similarly, clinicians are aware of the potential dev-
astating effects of TED in INS, but whether primary prophy-
laxis is warranted (for all children with INS or for a specific
subgroup) is unknown. Further work is also needed tominimise
the long-term CVD risk factor of dyslipidaemia in the INS
population. Additionally, novel management strategies, such
as modifying sialylation of the circulating glycoprotein
angiopoietin-like 4, have shown promising results in rodent
models of INS, and studies translating this to human disease
are eagerly awaited [196, 197]. Substantial progress has been
made in our ability to manage INS since the introduction of
glucocorticoids and antibiotics in the second half of the last
century, but continued progress through clinical trials is needed.
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